repligen
reports
third
quarter
financial
results
updates
full
year
financial
guidance
reports
record
quarterly
revenue
million
strong
margin
expansion
overall
revenue
grew
organic
growth
raises
revenue
guidance
million
overall
revenue
growth
full
year
representing
organic
growth
completes
acquisition
solutions
announces
agreement
acquire
bioprocess
systems
innovator
artesyn
biosolutions
waltham
globe
newswire
repligen
corporation
nasdaq
rgen
life
sciences
company
focused
bioprocessing
technology
leadership
today
reported
financial
results
third
quarter
provided
press
release
financial
highlights
month
periods
ended
september
updates
financial
guidance
fiscal
year
access
information
today
webcast
conference
call
tony
j
hunt
president
chief
executive
officer
said
pleased
momentum
third
quarter
reporting
million
revenue
robust
organic
growth
covid
programs
accounted
approximately
revenue
quarter
approximately
revenue
growth
continued
see
strong
revenue
order
demand
covid
customers
gene
therapy
accounts
drove
accelerated
growth
across
franchises
filtration
performing
exceptionally
well
direct
product
orders
positioning
us
well
excellent
finish
strong
start
hunt
added
addition
strong
business
performance
delighted
close
deal
acquire
solutions
also
sign
agreement
acquire
artesyn
biosolutions
acquisitions
broaden
strengthen
systems
strategy
systems
consumables
including
flow
path
assemblies
come
together
enhanced
customer
offering
meaningful
process
yield
financial
highlights
third
quarter
revenue
increased
reported
organically
reach
quarterly
record
million
gross
margin
gaap
increase
points
adjusted
gross
margin
increase
points
compared
third
quarter
operating
margin
gaap
increase
points
adjusted
operating
margin
increase
points
compared
third
quarter
fully
diluted
eps
gaap
increased
compared
third
quarter
adjusted
fully
diluted
eps
increased
compared
third
quarter
financial
details
third
quarter
first
nine
months
revenue
total
revenue
third
quarter
increased
million
compared
million
third
quarter
gain
reported
constant
currency
organic
growth
total
revenue
first
nine
months
increased
million
compared
million
first
nine
months
gain
reported
constant
currency
organic
growth
gross
profit
gross
margin
gross
profit
gaap
third
quarter
million
increase
million
representing
gross
margin
adjusted
gross
profit
third
quarter
million
increase
million
representing
gross
margin
gross
profit
gaap
first
nine
months
million
increase
million
representing
gross
margin
adjusted
gross
profit
first
nine
months
million
increase
million
representing
gross
margin
operating
income
operating
income
gaap
third
quarter
million
increase
million
compared
million
third
quarter
adjusted
operating
income
third
quarter
million
increase
million
compared
million
third
quarter
operating
income
gaap
first
nine
months
million
increase
million
compared
million
first
nine
months
adjusted
operating
income
first
nine
months
million
increase
million
compared
million
first
nine
months
net
income
net
income
gaap
third
quarter
million
increase
million
compared
million
third
quarter
adjusted
net
income
third
quarter
million
increase
million
compared
million
third
quarter
net
income
gaap
first
nine
months
million
increase
million
compared
million
first
nine
months
adjusted
net
income
first
nine
months
million
increase
million
compared
million
first
nine
months
earnings
per
share
earnings
per
share
gaap
third
quarter
increased
fully
diluted
basis
compared
third
quarter
adjusted
eps
third
quarter
increased
fully
diluted
basis
compared
period
earnings
per
share
gaap
first
nine
months
increased
fully
diluted
basis
compared
first
nine
months
adjusted
eps
first
nine
months
increased
fully
diluted
basis
compared
first
nine
months
ebitda
ebitda
financial
measure
increased
million
third
quarter
compared
million
third
quarter
adjusted
ebitda
third
quarter
increased
million
compared
million
third
quarter
ebitda
increased
million
first
nine
months
compared
million
first
nine
months
adjusted
ebitda
first
nine
months
increased
million
compared
million
first
nine
months
cash
cash
cash
equivalents
september
million
increase
million
million
december
reconciliations
gaap
adjusted
figures
well
ebitda
adjusted
ebitda
detailed
reconciliation
tables
included
later
press
release
financial
guidance
financial
guidance
fiscal
year
based
expectations
existing
business
includes
financial
impact
acquisitions
c
technologies
closed
may
engineered
molding
technology
closed
july
solutions
closed
october
guidance
include
impact
proposed
acquisition
artesyn
biosolutions
expected
close
fourth
quarter
guidance
also
excludes
impact
potential
additional
acquisitions
future
fluctuations
foreign
currency
exchange
rates
fiscal
year
guidance
total
revenue
projected
range
million
increase
previous
guidance
million
updated
revenue
guidance
includes
approximately
million
projected
revenue
solutions
reflects
overall
revenue
growth
organic
revenue
growth
range
covid
programs
expected
account
approximately
revenue
gross
margin
expected
range
gaap
basis
compared
previous
guidance
income
operations
expected
range
million
gaap
basis
increase
previous
guidance
million
adjusted
income
operations
expected
range
million
increase
previous
guidance
million
net
income
expected
range
million
gaap
basis
increase
previous
guidance
million
adjusted
net
income
expected
range
million
increase
previous
guidance
million
current
guidance
reflects
adjusted
tax
rate
adjusted
income
compared
previous
guidance
fully
diluted
eps
gaap
expected
range
increase
previous
guidance
adjusted
fully
diluted
eps
expected
range
increase
previous
guidance
guidance
fiscal
year
excludes
following
items
million
estimated
acquisition
integration
expenses
million
cost
product
revenue
million
r
million
selling
general
administrative
expense
sg
expected
inventory
charges
million
related
acquisitions
engineered
molding
technology
solutions
million
estimated
intangible
amortization
expense
million
cost
product
revenue
million
sg
million
interest
expense
income
expense
related
convertible
debt
notes
guidance
fiscal
year
includes
income
tax
expense
million
representing
tax
impact
acquisition
integration
inventory
intangible
amortization
expenses
well
interest
expenses
related
convertible
debt
notes
reconciliations
gaap
adjusted
guidance
detailed
tables
included
later
press
release
conference
call
repligen
host
conference
call
webcast
today
november
est
discuss
third
quarter
financial
results
corporate
developments
conference
call
accessible
dialing
domestic
callers
international
callers
passcode
required
live
call
addition
webcast
accessible
via
investor
relations
section
company
website
conference
call
webcast
archived
period
time
following
live
event
replay
numbers
canada
international
callers
replay
listeners
must
provide
passcode
measures
financial
performance
supplement
financial
statements
presented
basis
generally
accepted
accounting
principles
gaap
following
measures
financial
performance
included
release
revenue
growth
rate
constant
currency
adjusted
gross
profit
adjusted
gross
margin
adjusted
income
operations
adjusted
operating
margin
earnings
interest
taxes
depreciation
amortization
ebitda
adjusted
ebitda
adjusted
net
income
adjusted
net
income
per
share
adjusted
earnings
per
diluted
share
eps
adjusted
cost
sales
adjusted
research
development
expense
adjusted
sg
adjusted
income
tax
expense
adjusted
income
tax
rate
company
provides
organic
revenue
growth
rates
constant
currency
exclude
impact
foreign
currency
translation
impact
acquisition
revenue
current
year
periods
prior
year
comparable
order
facilitate
comparison
current
revenue
performance
past
revenue
performance
company
provides
revenue
growth
rates
constant
currency
order
facilitate
comparison
current
revenue
performance
past
revenue
performance
calculate
revenue
growth
rates
constant
currency
company
converts
actual
net
sales
local
currency
dollars
using
constant
foreign
currency
exchange
rates
current
prior
period
company
financial
results
guidance
exclude
impact
acquisition
integration
costs
inventory
charges
intangible
amortization
costs
related
company
acquisitions
well
interest
expenses
related
company
convertible
debt
related
impact
tax
charges
costs
excluded
management
believes
expenses
direct
correlation
future
business
operations
resulting
charges
recorded
accurately
reflect
performance
ongoing
operations
period
charges
recorded
reconciliation
gaap
adjusted
financial
measures
well
ebitda
adjusted
ebitda
included
attachment
press
release
analyzing
company
operating
performance
guidance
investors
consider
measures
substitutable
comparable
financial
measures
prepared
accordance
gaap
repligen
corporation
repligen
corporation
global
life
sciences
company
develops
commercializes
highly
innovative
bioprocessing
technologies
systems
increase
efficiencies
process
manufacturing
biological
drugs
inspiring
advances
bioprocessing
customers
serve
primarily
biopharmaceutical
drug
developers
contract
development
manufacturing
organizations
cdmos
worldwide
corporate
headquarters
located
waltham
usa
additional
administrative
manufacturing
operations
rancho
dominguez
ca
marlborough
auburn
bridgewater
nj
clifton
park
ny
dallas
tx
ravensburg
germany
breda
netherlands
lund
sweden
following
constitutes
safe
harbor
statement
private
securities
litigation
reform
act
press
release
contains
statements
made
pursuant
safe
harbor
provisions
section
securities
act
amended
section
securities
exchange
act
amended
investors
cautioned
statements
press
release
strictly
historical
statements
including
without
limitation
express
implied
statements
guidance
regarding
current
future
financial
performance
position
including
cash
investment
position
demand
markets
operate
expected
performance
business
expected
performance
c
technologies
engineered
molding
technology
solutions
businesses
expected
closing
acquisition
artesyn
biosolutions
expected
performance
success
strategic
partnerships
management
strategy
plans
objectives
future
operations
acquisitions
product
development
sales
selling
general
administrative
expenditures
intellectual
property
development
manufacturing
plans
availability
materials
product
adequacy
capital
resources
financing
plans
projected
impact
response
coronavirus
pandemic
business
global
economies
constitute
statements
identified
words
like
believe
expect
may
seek
anticipate
could
similar
expressions
statements
subject
number
risks
uncertainties
could
cause
actual
results
differ
materially
anticipated
including
without
limitation
risks
associated
following
effect
coronavirus
pandemic
including
mitigation
efforts
economic
effects
business
operations
operations
customers
suppliers
ultimate
impact
coronavirus
pandemic
business
financial
results
ability
successfully
grow
bioprocessing
business
including
result
acquisition
commercialization
partnership
opportunities
ability
successfully
integrate
acquisitions
ability
develop
commercialize
products
market
acceptance
products
ability
integrate
c
technologies
engineered
molding
technology
solutions
businesses
successfully
business
achieve
expected
benefits
acquisitions
reduced
demand
products
adversely
impacts
future
revenues
cash
flows
results
operations
financial
condition
ability
compete
larger
better
financed
bioprocessing
pharmaceutical
biotechnology
companies
compliance
food
drug
administration
emea
regulations
volatile
stock
price
risks
detailed
repligen
annual
report
form
year
ended
december
quarterly
report
form
quarter
ended
march
file
securities
exchange
commission
reports
repligen
periodically
files
securities
exchange
commission
actual
results
may
differ
materially
repligen
contemplated
statements
statements
reflect
management
current
views
repligen
undertake
update
statements
reflect
change
views
events
circumstances
occur
date
hereof
except
required
law
repligen
contact
sondra
newman
global
head
investor
relations
investors
repligen
corporation
condensed
consolidated
statements
operations
unaudited
amounts
thousands
except
share
per
share
data
three
months
ended
september
nine
months
ended
september
revenue
product
revenue
royalty
revenue
total
revenue
costs
expenses
cost
product
revenue
research
development
selling
general
administrative
income
operations
investment
income
loss
extinguishment
debt
interest
expense
expense
income
net
income
income
taxes
income
tax
provision
net
income
earnings
per
share
basic
diluted
weighted
average
shares
outstanding
basic
diluted
balance
sheet
data
september
december
cash
cash
equivalents
marketable
securities
working
capital
total
assets
obligations
accumulated
earnings
stockholders
equity
repligen
corporation
reconciliation
gaap
income
operations
adjusted
income
operations
unaudited
amounts
thousands
three
months
ended
september
nine
months
ended
september
gaap
income
operations
adjustments
income
loss
operations
acquisition
integration
costs
intangible
amortization
inventory
charges
adjusted
income
operations
repligen
corporation
reconciliation
gaap
net
income
adjusted
net
income
unaudited
amounts
thousands
three
months
ended
september
nine
months
ended
september
gaap
net
income
adjustments
net
income
acquisition
integration
costs
inventory
charges
intangible
amortization
loss
extinguishment
debt
interest
expense
tax
effect
charges
adjusted
net
income
repligen
corporation
reconciliation
gaap
net
income
per
share
adjusted
net
income
per
share
unaudited
three
months
ended
september
nine
months
ended
september
gaap
net
income
per
share
diluted
adjustments
net
income
per
share
diluted
acquisition
integration
costs
inventory
charges
intangible
amortization
loss
extinguishment
debt
interest
expense
tax
effect
charges
adjusted
net
income
per
share
diluted
totals
may
add
due
rounding
repligen
corporation
reconciliation
gaap
net
income
adjusted
ebitda
unaudited
amounts
thousands
three
months
ended
september
nine
months
ended
september
gaap
net
income
adjustments
investment
income
interest
expense
tax
provision
depreciation
amortization
ebitda
adjustments
acquisition
integration
costs
loss
extinguishment
debt
inventory
charges
adjusted
ebitda
includes
amortization
milestone
payments
accordance
gaap
ended
september
repligen
corporation
reconciliation
gaap
cost
sales
adjusted
cost
sales
unaudited
amounts
thousands
three
months
ended
september
nine
months
ended
september
gaap
cost
sales
adjustment
cost
sales
acquisition
integration
costs
inventory
charges
intangible
amortization
adjusted
cost
sales
repligen
corporation
reconciliation
gaap
r
expense
adjusted
r
expense
unaudited
amounts
thousands
three
months
ended
september
nine
months
ended
september
gaap
r
adjustment
r
acquisition
integration
costs
adjusted
r
repligen
corporation
reconciliation
gaap
sg
expense
adjusted
sg
expense
unaudited
amounts
thousands
three
months
ended
september
nine
months
ended
september
gaap
sg
expense
adjustments
sg
expense
acquisition
integration
costs
intangible
amortization
adjusted
sg
expense
